Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study was to evaluate the safety, infectivity, and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants 6 to 24 months of age. This study was a companion study to CIR 311.
Epistemonikos ID: 3651fd13760b3ff8242cd92eb8e67e8e1f8ca809
First added on: Sep 12, 2018